Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$9.42 USD

9.42
363,633

+0.03 (0.32%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $9.42 0.00 (0.00%) 4:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Prothena Rallies on Multi-Year Collaboration With Celgene

by Zacks Equity Research

Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.

    Zacks Equity Research

    Prothena (PRTA) Up 8.7% Since Earnings Report: Can It Continue?

    by Zacks Equity Research

    Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Zacks Equity Research

      Options Traders Expect Huge Moves in Prothena (PRTA) Stock

      by Zacks Equity Research

      Investors in Prothena (PRTA) need to pay close attention to the stock based on moves in the options market lately.

        Zacks Equity Research

        FDA Accepts Acorda's NDA for Parkinson's Disease Candidate

        by Zacks Equity Research

        FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.

          Zacks Equity Research

          Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses

          by Zacks Equity Research

          Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.

            Zacks Equity Research

            Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?

            by Zacks Equity Research

            Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.

              Zacks Equity Research

              Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?

              by Zacks Equity Research

              Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.

                Zacks Equity Research

                Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija

                by Zacks Equity Research

                Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.

                  Zacks Equity Research

                  Acorda Stock Up Despite Phase III Trial on Tozadenant Stops

                  by Zacks Equity Research

                  Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.

                    Zacks Equity Research

                    Acorda Reports Death in Parkinson's Trials, Stock Down 40%

                    by Zacks Equity Research

                    Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.